MwanzoBMRN • NASDAQ
add
Biomarin Pharmaceutical Inc
Bei iliyotangulia
$ 52.52
Bei za siku
$ 51.86 - $ 52.76
Bei za mwaka
$ 51.02 - $ 73.51
Thamani ya kampuni katika soko
10.04B USD
Wastani wa hisa zilizouzwa
2.56M
Uwiano wa bei na mapato
19.57
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 776.13M | 4.08% |
Matumizi ya uendeshaji wa biashara | 682.74M | 53.98% |
Mapato halisi | -30.74M | -128.98% |
Kiwango cha faida halisi | -3.96 | -127.85% |
Mapato kwa kila hisa | 0.12 | -86.81% |
EBITDA | -28.20M | -121.22% |
Asilimia ya kodi ya mapato | -16.79% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 1.48B | 58.83% |
Jumla ya mali | 7.61B | 11.15% |
Jumla ya dhima | 1.56B | 8.37% |
Jumla ya hisa | 6.06B | — |
hisa zilizosalia | 192.11M | — |
Uwiano wa bei na thamani | 1.67 | — |
Faida inayotokana na mali | -1.55% | — |
Faida inayotokana mtaji | -1.76% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -30.74M | -128.98% |
Pesa kutokana na shughuli | 368.68M | 66.46% |
Pesa kutokana na uwekezaji | -330.96M | -1,948.42% |
Pesa kutokana na ufadhili | -2.17M | 99.57% |
Mabadiliko halisi ya pesa taslimu | 36.29M | 112.23% |
Mtiririko huru wa pesa | 114.03M | -31.13% |
Kuhusu
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
Mac 1997
Makao Makuu
Tovuti
Wafanyakazi
3,040
